Heron Therapeutics financials
$0.3060+4.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M | $88.6M | $146.0M | $77.5M | $30.8M | $1.3M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | $40.3M | $52.4M | $84.3M | $50.0M | $26.2M | $1.2M |
| Gross margin | 73.3% | 73.2% | 48.8% | 49.0% | 46.7% | 59.2% | 57.8% | 64.5% | 85.1% | 97.3% |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M | -$228.2M | -$210.7M | -$183.9M | -$194.6M | -$170.9M |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M | -$227.3M | -$204.7M | -$178.8M | -$197.5M | -$173.1M |
| Net margin | −13.0% | −9.4% | −87.0% | −169.1% | −255.6% | −256.4% | −140.3% | −230.8% | −641.9% | −13537.4% |
| Diluted EPS | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 | $-2.50 | $-2.50 | $-2.44 | $-3.65 | $-4.56 |
| EBITDA | -$224.0K | -$9.0M | -$107.7M | -$171.8M | -$214.8M | -$225.3M | -$208.7M | -$182.4M | -$193.0M | -$169.8M |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M | -$184.8M | -$124.6M | -$191.8M | -$170.3M | -$134.1M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M | -$191.6M | -$131.7M | -$201.0M | -$172.9M | -$137.2M |
| Diluted shares | 166.7M | 152.4M | 138.1M | 108.9M | 98.5M | 90.8M | 81.8M | 73.2M | 54.0M | 37.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M | $105.1M |
| Short-term investments | $18.0M | $33.5M | $51.7M | $69.5M | $67.0M | $103.4M |
| Total debt | $140.6M | $174.7M | $173.8M | $149.3M | $149.1M | $7.1M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M | $353.6M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M | $117.1M |
| Shareholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M | $236.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology